PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩1,428 per share · Prices as of the 2026-10-02 close
Namyang Dairy returned to annual profit in 2025 for the first time in six years and kept growing revenue and operating profit in the first half of 2026, even as signs of majority shareholder Hahn & Company's capital-recovery moves and lingering legacy owner-risk issues persist.
2025 consolidated operating profit reached KRW 5.17bn and owners' net profit KRW 7.11bn, marking the first annual profit in six years.
In H1 2026, revenue rose to KRW 483.2bn (+7.9%) and operating profit to KRW 1.8bn (+79.5%), extending the growth trend.
The share of overseas sales expanded from 4.5% to 9.6%, making exports a key driver of the earnings recovery.
The 'Take Fit' protein brand and an expanding coffee lineup underpinned domestic sales growth.
Market observers have noted signs of majority shareholder Hahn & Company pursuing capital recovery via stake sales and dividend recapitalization.
Founded in 1964, Namyang Dairy is a dairy specialist whose core businesses span milk, infant formula, and fermented milk, alongside coffee, health functional foods, and the ice cream brand Baekmidang.
Under the standard industry classification for liquid milk and other dairy manufacturing, it is categorized as the No. 4 player in the industry.
In H1 2026, milk products remained the largest revenue category at 48.9%, though this was down from 54.4% a year earlier, while the 'other products' category including Chocoemong and Take Fit expanded from 24.3% to 29.2%, and infant formula edged up from 21.3% to 21.9%.
Key products include 'Delicious Milk GT,' 'Chocoemong,' the fermented milk brand 'Bulgaris,' the protein brand 'Take Fit,' and coffee mixes 'French Cafe' and 'Lucas Nine.' Subsidiary ice cream brand Baekmidang posted H1 2026 revenue of KRW 16.0bn (+34.8%) and swung from an operating loss of KRW 50mn a year earlier to an operating profit of KRW 560mn.
Competitors include Maeil Dairies, Seoul Milk Cooperative, and hy (formerly Korea Yakult), and the domestic dairy market continues to see share competition among large incumbents.
The largest shareholder is Hahn & Company 19th Co., Ltd., a vehicle of private equity firm Hahn & Company, which secured control following a 2024 Supreme Court ruling and shareholder meeting and now runs the company under an executive-officer system.
The company has shifted its business model from volume-driven sales toward a profitability-focused structure, concurrently trimming low-margin distribution channels and product lines.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩232.1B | ₩900M | 0.4% |
| 2025Q3 | ₩237.5B | ₩1.7B | 0.7% |
| 2025Q4 | ₩229B | ₩2.5B | 1.1% |
| 2026Q1 | ₩225.2B | ₩500M | 0.2% |
| 2026Q2 | ₩258B | ₩1.3B | 0.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩964.7B | -₩86.8B | -₩78.4B | −9.0% | −10.6% | 22.3% |
| 2023 | ₩996.8B | -₩72.4B | -₩67.1B | −7.3% | −9.9% | 16.6% |
| 2024 | ₩952.8B | -₩9.8B | ₩200M | −1.0% | 0.0% | 14.6% |
| 2025 | ₩914.1B | ₩5.2B | ₩7.1B | 0.6% | 0.7% | 15.4% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
Based on confirmed financials, Namyang Dairy posted three consecutive years of operating losses—revenue of KRW 964.7bn with an operating loss of KRW 86.8bn in 2022, revenue of KRW 996.8bn with a loss of KRW 72.4bn in 2023, and revenue of KRW 952.8bn with a loss of KRW 9.8bn in 2024—before turning profitable in 2025 with revenue of KRW 914.1bn, operating profit of KRW 5.17bn (an operating margin of 0.6%), and owners' net profit of KRW 7.11bn.
Notably, revenue actually declined versus 2022 even as losses narrowed and the company returned to profit. On a quarterly basis, operating profit expanded sequentially from KRW 0.93bn on revenue of KRW 232.1bn in Q2 2025, to KRW 1.70bn on KRW 237.5bn in Q3, and KRW 2.47bn on KRW 229.0bn in Q4.
However, in Q1 2026 operating profit fell to KRW 0.52bn on revenue of KRW 225.2bn, even as owners' net profit jumped to KRW 6.31bn. This was driven by a one-off item—a compensation deposit related to former chairman Hong Won-sik's family's embezzlement and breach-of-trust case, recognized as other non-operating income.
In Q2 2026, revenue rose to KRW 258.0bn, operating profit to KRW 1.28bn, and owners' net profit to KRW 1.52bn, with revenue up 11.2% year-over-year and operating profit continuing to grow.
Cumulative owners' net profit over the trailing four quarters (Q3 2025 through Q2 2026) reached KRW 12.86bn, though this window includes the one-off gain from Q1 2026, so the base effect may fade in coming quarters.
On the cash flow side, operating cash flow was KRW 26.85bn in 2025, down from KRW 34.77bn in 2024, but a clear improvement from the negative cash flows recorded in 2022–2023.
South Korea's dairy industry faces structural demand softness in milk and infant formula amid a declining birth rate, and industry reports have noted that falling births are reducing milk consumption while imported dairy products and alternative foods expand their market presence.
In this environment, observers argue that domestic dairy makers must go beyond cost-cutting alone and identify new growth categories.
Namyang Dairy has responded by reducing its reliance on milk products and diversifying into protein, coffee, and health functional foods, a shift confirmed by the H1 change in sales mix, with the milk category's share falling and the other-products category rising.
Rivals such as Maeil Dairies and Seoul Milk Cooperative are pursuing similar portfolio diversification and overseas channel expansion, creating a competitive landscape that requires simultaneously defending domestic share and developing new export markets.
In the coffee category, product segmentation aligned with zero-sugar and low-sugar trends is underway, and Namyang has responded with smaller, lower-priced ready-to-drink cups and zero-sugar latte variants.
The protein beverage market is growing amid the broader healthy-pleasure consumption trend, emerging as a new growth axis across the domestic food industry.
When reporting H1 results, the company stated it would strengthen its sustainable growth base in the second half through overseas business expansion, competitiveness in growth product categories, and upgrades to key distribution channels.
On the export front, the company participated in a presidential economic delegation and signed export memorandums of understanding with a major Vietnamese distributor in April and a major Mongolian distributor in July, with Vietnam featuring a shift to a direct-trade structure via the country's largest distributor to re-attempt market entrenchment.
Export items have also diversified beyond infant formula to include freeze-dried coffee, French Cafe coffee mix, and Take Fit products.
On the product side, the coffee lineup continues to expand: H1 2026 coffee-mix sales rose 11.5% year-over-year, and in August the company launched two 200mL ready-to-drink cup coffee items and four zero-sugar latte variants.
The Take Fit protein brand has broadened its lineup with Extreme, Monster, Treadmill, and Booster products, driving 76.1% H1 sales growth. Subsidiary Baekmidang's swing to profitability has also continued, increasing the profit contribution from non-dairy segments.
That said, reports indicate majority shareholder Hahn & Company has sold some shares on the open market and used dividend recapitalization to raise funds, making it worth monitoring both the pace of capital recovery and the direction of the company's financial policy.
The share price relative to net asset value has tended to trade below historical book value levels, reflecting a cautious market stance relative to the company's capital base.
On the earnings side, the price-to-earnings multiple appears elevated, but this largely reflects the still-small profit base in the early stage of the turnaround rather than an absolute valuation judgment.
On shareholder returns, the company has recently combined a year-end dividend with a special dividend to significantly increase payout size, confirming a clear direction in shareholder-return policy, although some observers link this to the majority shareholder's capital-recovery strategy.
The shift from three consecutive years of losses to profitability itself signals a directional improvement in performance, but because profit remains modest relative to revenue, the durability and scale of that improvement warrant continued observation.
Overall, the current trading multiples appear to reflect a transitional phase blending the legacy of past losses with the recent return to profit.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
H1 2026 overseas revenue rose to KRW 46.6bn, up 130% year-over-year, and its share of total revenue more than doubled from 4.5% to 9.6%.
In Vietnam, the company shifted to a direct-trade structure with the country's largest distributor to re-attempt market entrenchment, while also expanding into Mongolia and other markets. Export items have diversified from infant-formula-centric to include coffee and protein products, broadening the growth base.
The Take Fit protein brand's H1 sales grew 76.1%, and coffee-mix sales rose 11.5%, reducing the company's reliance on milk products. The milk category's share fell from 54.4% to 48.9% year-over-year, while the other-products category expanded from 24.3% to 29.2%.
This is a numerically confirmed instance of the strategy to offset milk demand softness from declining births with other growth categories.
Ice cream brand Baekmidang posted H1 2026 revenue of KRW 16.0bn, up 34.8% year-over-year, and swung from an operating loss of KRW 50mn to an operating profit of KRW 560mn. The growing profit contribution from this non-dairy segment supports the diversification of the group's overall earnings structure.
Structural demand for domestic milk and infant formula is slowing amid the declining birth rate, while imported dairy products and alternative foods expand their market presence. The declining share of milk products in Namyang Dairy's sales mix reflects this structural pressure. Overseas revenue growth is offsetting some of this, but it still accounts for under 10% of total sales.
Hahn & Company is reported to have sold some shares on the open market and used share-collateralized dividend recapitalization to raise funds, with the dividend payout ratio reportedly exceeding 150%.
The possibility of asset sales, including the headquarters building, has also been raised, warranting attention to how such recovery strategies might affect reinvestment capacity or the pace of growth investment.
The company has pushed back on the capital-recovery interpretation, characterizing share cancellations as routine shareholder-value activities.
Former chairman Hong Won-sik has continued legal disputes with the company even after relinquishing control, including a lawsuit seeking severance payment. Industry observers have raised concerns that such ongoing litigation could affect the pace of brand-image recovery and rebuilding consumer trust.
Litigation related to former chairman Hong Won-sik has continued even after the change of control, and reports have noted disputes between former and current management escalating into legal conflicts. If such disputes persist, they could weigh on the pace of management normalization and brand-image recovery.
Structural demand softness in the domestic milk and infant-formula market continues amid the declining birth rate.
Competition from imported dairy products and alternative foods is also intensifying, making the pace at which overseas revenue growth and new product categories offset domestic demand softness a key variable.
Reports of the majority shareholder simultaneously pursuing stake sales, dividend recapitalization, and a high dividend payout policy warrant attention to how these cash flows might affect the company's reinvestment capacity or future growth investment.
The company has characterized these as routine shareholder-value activities, leaving room for differing interpretations.
Around the Q3 2026 earnings disclosure, it will be worth checking whether the expansion in overseas revenue share and growth in the Take Fit and coffee categories continue, and how net profit trends once the base effect from the Q1 2026 one-off gain fades.
It is worth monitoring for disclosures related to further stake sales by Hahn & Company, additional recapitalization, or asset sales such as the headquarters or Baekmidang flagship building, to gauge the pace of capital recovery.
Follow-up disclosures or reports should confirm how much the April export MOU with a Vietnamese distributor and the July MOU with a Mongolian distributor actually translate into revenue, and whether the benefits of the direct-trade structure shift persist.
The outcome of legal disputes with the former chairman, including the severance-payment lawsuit, could potentially be reflected in future financial statements, so related disclosures or court rulings should continue to be monitored.
Namyang Dairy turned from three consecutive years of losses in 2022–2024 to profitability in 2025, and continued that improving trend into H1 2026 with growth in both revenue and operating profit.
The growth axis stems from reducing reliance on milk products while building out export, protein, and coffee growth categories, a shift numerically confirmed in the H1 sales mix.
However, the surge in Q1 2026 net profit was heavily driven by a one-off item—a compensation deposit related to former chairman Hong Won-sik's family case—and the fading of this base effect in subsequent quarters should be factored in.
Reports of majority shareholder Hahn & Company simultaneously pursuing stake sales, dividend recapitalization, and a high dividend payout policy make the balance between its capital-recovery strategy and the company's long-term reinvestment capacity worth watching.
Legacy owner-risk issues, including ongoing legal disputes with former chairman Hong, also remain unresolved. Overall, while the directional improvement in performance is confirmed, its durability, magnitude, and governance-related uncertainties warrant continued observation.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.